Clinical trial · Interventional
Temporal Variation in Exhaled Volatile Organic Compounds in Esophageal Cancer Patients
Temporal Variation in Exhaled Volatile Organic Compounds in Response to Therapeutic Intervention in Esophageal Cancer Patients
NCT06453993CI-TRIAL-00080185completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate whether exhaled breath can be used to detect and monitor esophageal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exhaled VOC breath test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Investigate whether exhaled breath can be used to detect and monitor esophageal cancer.
- description
- The procedures will include collecting participant's personal information and samples of participant's exhaled breath, urine, and saliva.
- interventionNames
- Other: Exhaled VOC breath test
Primary outcomes (1)
- measure
- Exhaled breath and urinary VOC concentrations as biomarkers of esophageal cancer
- timeFrame
- Before commencing treatment for esophageal cancer
- description
- The composition and concentration of volitile organic compounds (VOC) in exhaled breath and urinary samples will be assessed to establish a VOC signature of esophogeal cancer
Secondary outcomes (3)
- measure
- Changes in VOC concentrations that occur in response to therapeutic intervention
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18-90 years * Newly-diagnosed, treatment naïve patients with esophageal and/or gastroesophageal junctional cancer * Planning to undergo curative treatment, including neoadjuvant chemoradiotherapy and surgical resection Exclusion Criteria: * Pregnant females * Without malignant esophageal disease * Malignancy at a secondary site other than the esophagus * Undergoing palliative treatment for esophageal cancer * Not receiving neoadjuvant chemoradiotherapy and surgical resection for esophageal cancer * Inability or unwillingness to provide written informed consent
References
Publications (2)
- RESULTKamal F, Kumar S, Edwards MR, Veselkov K, Belluomo I, Kebadze T, Romano A, Trujillo-Torralbo MB, Shahridan Faiez T, Walton R, Ritchie AI, Wiseman DJ, Laponogov I, Donaldson G, Wedzicha JA, Johnston SL, Singanayagam A, Hanna GB. Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath during Pulmonary Infection. Am J Respir Crit Care Med. 2021 Nov 1;204(9):1075-1085. doi: 10.1164/rccm.202103-0660OC. PMID 34319857
- RESULTAntonowicz S, Bodai Z, Wiggins T, Markar SR, Boshier PR, Goh YM, Adam ME, Lu H, Kudo H, Rosini F, Goldin R, Moralli D, Green CM, Peters CJ, Habib N, Gabra H, Fitzgerald RC, Takats Z, Hanna GB. Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. Nat Commun. 2021 Mar 5;12(1):1454. doi: 10.1038/s41467-021-21800-5. PMID 33674602